Nivolumab as Programmed Death-1 (PD-1) Inhibitor for Targeted Immunotherapy in Tumor

Targeted immunotherapy has become the most promising approach for tumor patients. Programmed death-1 (PD-1), an inhibitory receptor expressed on activated T cells, can reverse immune suppression and release T cell activation. Nivolumab, a fully human immunoglobulin G4 PD-1 immune checkpoint inhibito...

Descripción completa

Detalles Bibliográficos
Autores principales: Guo, Liting, Zhang, Haijun, Chen, Baoan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Ivyspring International Publisher 2017
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5332892/
https://www.ncbi.nlm.nih.gov/pubmed/28261342
http://dx.doi.org/10.7150/jca.17144

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5332892/
https://www.ncbi.nlm.nih.gov/pubmed/28261342
http://dx.doi.org/10.7150/jca.17144

Ejemplares similares